Want to see AU:HPC full AI Analyst Report?
HPC Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume65.65K
Average Volume (3M)1.21M
Market Cap
AU$2.15M
Enterprise ValueAU$90.91K
Total Cash (Recent Filing)AU$1.12M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding537,988,460
10 Day Avg. Volume3,315,133
30 Day Avg. Volume1,207,806
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.51
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageReported zero debt in 2024–2025 materially lowers solvency risk and gives management longer optionality to raise capital or restructure financing without servicing existing debt. Over 2–6 months this supports strategic flexibility for funding product development, marketing, or working capital needs.
Consumer Health / Hydration FocusA concentrated product focus in hydration/electrolytes targets resilient consumer-health demand and repeat-purchase categories. Structurally, health and wellness trends support steady long-term consumption and brand building potential, which can enable margin recovery if distribution and marketing scale efficiently.
Demonstrated Occasional ProfitabilityThe company produced a strong net profit margin in 2024, showing the business can achieve profitability under certain conditions. This indicates that with stabilized revenue or better cost control, operational levers exist to return to profit, providing a realistic pathway to durable improvement within months.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow, with 2025 OCF worsening to ~-3.8M, implies the business cannot self-fund. Over a 2–6 month horizon this elevates funding risk, increases likelihood of external financing or dilution, and constrains investment in distribution, product development, or working capital.
Revenue Volatility And Recent DeclineHighly volatile revenue and a material decline in 2025 undermine predictability needed to achieve scale and operating leverage. Persistent top-line instability impairs long-term margin recovery and strategic planning, making sustainable growth and durable profitability harder to realize without structural changes.
Negative Gross Profit & Large Operating LossesA negative gross profit and deep operating losses highlight that the core business is not covering direct costs, indicating structural margin issues. Without sustained gross margin recovery or a business-model reset, operating losses will continue to erode equity and limit ability to compete or invest over the medium term.
Hydration Pharmaceuticals Co. Ltd. News
HPC FAQ
What was Hydration Pharmaceuticals Co. Ltd.’s price range in the past 12 months?
Hydration Pharmaceuticals Co. Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Hydration Pharmaceuticals Co. Ltd.’s market cap?
Hydration Pharmaceuticals Co. Ltd.’s market cap is AU$2.15M.
When is Hydration Pharmaceuticals Co. Ltd.’s upcoming earnings report date?
Hydration Pharmaceuticals Co. Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 55 days.
How were Hydration Pharmaceuticals Co. Ltd.’s earnings last quarter?
Hydration Pharmaceuticals Co. Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Hydration Pharmaceuticals Co. Ltd. overvalued?
According to Wall Street analysts Hydration Pharmaceuticals Co. Ltd.’s price is currently Overvalued.
Does Hydration Pharmaceuticals Co. Ltd. pay dividends?
Hydration Pharmaceuticals Co. Ltd. does not currently pay dividends.
What is Hydration Pharmaceuticals Co. Ltd.’s EPS estimate?
Hydration Pharmaceuticals Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hydration Pharmaceuticals Co. Ltd. have?
Hydration Pharmaceuticals Co. Ltd. has 537,988,460 shares outstanding.
What happened to Hydration Pharmaceuticals Co. Ltd.’s price movement after its last earnings report?
Hydration Pharmaceuticals Co. Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hydration Pharmaceuticals Co. Ltd.?
Currently, no hedge funds are holding shares in AU:HPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hydration Pharmaceuticals Co. Ltd. Stock Smart Score
Company Description
Hydration Pharmaceuticals Co. Ltd.
The Hydration Pharmaceuticals Company Limited, established in 2001, provides a diverse portfolio of healthy hydration remedies, offered as liquids, tablets, and powders. Operating from its headquarters in San Diego, California, the company distributes these Hydralyte-branded items through both conventional retail outlets and digital e-commerce platforms across Australia, the United States, and Canada.
Technical Analysis
Options Prices
Currently, No data available
---